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Down syndrome (DS) is one of the leading causes of intellectual disability, and patients
with DS face various health issues, including learning and memory deficits, congenital
heart disease, Alzheimer’s disease (AD), leukemia, and cancer, leading to huge medical
and social costs. Remarkable advances on DS research have been made in improving
cognitive function in mouse models for future therapeutic approaches in patients.
Among the different approaches, DYRK1A inhibitors have emerged as promising
therapeutics to reduce DS cognitive deficits. DYRK1A is a dual-specificity kinase that
is overexpressed in DS and plays a key role in neurogenesis, outgrowth of axons and
dendrites, neuronal trafficking and aging. Its pivotal role in the DS phenotype makes it
a prime target for the development of therapeutics. Recently, disruption of DYRK1A
has been found in Autosomal Dominant Mental Retardation 7 (MRD7), resulting in
severe mental deficiency. Recent advances in the development of kinase inhibitors are
expected, in the near future, to remove DS from the list of incurable diseases, providing
certain conditions such as drug dosage and correct timing for the optimum long-term
treatment. In addition the exact molecular and cellular mechanisms that are targeted by
the inhibition of DYRK1A are still to be discovered.
Keywords: trisomy 21, neurodevelopmental disorder, mouse model, cognition, learning and memory, clinical trial,
DYRK1A and kinase inhibitors
INTRODUCTION
Since Down (1866) described patients with mental retardation and characteristic faces, Down
Syndrome (DS) has been recognized as one of the most common genetic disorders leading to
intellectual disability. DS results from the presence of an extra copy of all or part of chromosome 21
(Lejeune et al., 1959). The clinical presentation of DS is complex and variable. A few features occur
to some degree in every individual with trisomy 21, including 100% of patients with intellectual
disability, hypotonia, and cranio-facial dysmorphology, 75% with brachycephaly or 60% with
epicanthic fold, 40% with congenital heart disease, and an increased incidence of leukemia in DS
that is 10- to 20-fold higher than that in the general population (Antonarakis et al., 2004). The most
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disabling phenotype for patients is the impaired intellectual
and adaptive functioning, strongly contributed by defects
in hippocampal- and prefrontal cortex-dependent functions
(Pennington et al., 2003; Dierssen et al., 2009; Contestabile et al.,
2010; Lott and Dierssen, 2010). These deficits are associated
with both learning and short-term and long-term memory,
resulting in a delay in cognitive development (Nelson et al.,
2005) along with various aspects of language acquisition and
comprehension (Chapman and Hesketh, 2000; Abbeduto et al.,
2007). In the last decades, with better care and medical follow-
up, the life expectancy of people with DS is increasing and is
quickly approaching 60 years (Puri et al., 1995; Covelli et al.,
2016). However, because DS patients show accelerated aging,
including early onset dementia similar to Alzheimer’s disease
(AD) (Zigman, 2013), and the increase in life expectancy does
not follow the one observed in the general population or other
groups with intellectual disability (Coppus, 2013).
Down syndrome features have largely been attributed to the
overexpression of specific trisomic genes (Antonarakis et al.,
2004), even if non-coding element (Elton et al., 2010) or
DNA methylation (Lu and Sheen, 2013) could have significant
effect on DS phenotypes. Transcriptome analyses showed that
between 29 and 62% of trisomic genes are overexpressed by
a factor of 1.5 with some variability and depending on the
cell type (Saran et al., 2003; Aït Yahya-Graison et al., 2007;
Prandini et al., 2007; Sultan et al., 2007; Laffaire et al., 2009;
Moldrich et al., 2009) and that trisomy has an impact on
large number of genes located in domains all over the genome
(Letourneau et al., 2014). A few candidate genes have been
selected for therapeutic approaches because of their brain related
functions, their specific pattern of expression/localization and/or
their contribution to signaling pathways involved in cognitive
functions. In parallel, investigation of the relationship between
phenotype and genotype using a panel of rare DS patients with
only partial duplication of the chromosome 21 segment led to
the hypothesis of the DS chromosomal region (DCR), in which
a small set of genes (between D21S55-MX1) plays a major role in
the determination of DS phenotypes including the development
of cognitive disabilities (McCormick et al., 1989; Rahmani et al.,
1989; Korenberg, 1990; Delabar et al., 1993; Sinet et al., 1994;
Korbel et al., 2009; Lyle et al., 2009). Among the 33 genes in the
DCR, dual-specificity tyrosine phosphorylation-regulated kinase
1A (DYRK1A), which has been always found overexpressed in
DS patients and mouse models (Guimera et al., 1999; Dowjat
et al., 2007), has received considerable attention because of its
involvement in brain functions and processes that are altered
in DS, and in the early onset of neurofibrillary degeneration,
β-amyloidosis, neuronal loss and AD-like phenotypes in DS (Liu
et al., 2008; Wegiel et al., 2011).
DYRK1A IS A KINASE INVOLVED IN
NEURODEVELOPMENTAL PROCESS
AND BRAIN FUNCTION
DYRK1A is the homologue of the Drosophila minibrain (mnb)
which was named from the description of the brain phenotype
observed in hypomorphic mutant flies (Tejedor et al., 1995).
The DYRK family includes four additional mammalian subtypes
including DYRK1B, DYRK2, DYRK3, and DYRK4. DYRK
proteins show little sequence homology with other kinases
outside of their catalytic domains but are highly conserved
across species (Becker et al., 1998). DYRK1A can catalyze
its own activation through auto-phosphorylation of a single
tyrosine residue in its activation loop (Lochhead et al., 2005;
Soundararajan et al., 2013; Soppa and Becker, 2015).
DYRK1A is expressed during embryonic neurogenesis. First,
DYRK1A is transiently detected in preneurogenic region during
early mouse embryogenesis from 8 to 10.5 days postcoitum
(dpc). Then Dyrk1a expression was observed in cycling neuronal
progenitor cells of the ventricular and subventricular zones at
14.5 dpc (Hammerle et al., 2008). The authors proposed that
DYRK1A controls the mouse neuronal precursor exit from
differentiation, leaving the cells in a quiescent state ready to
differentiate while its expression is reduced (Hammerle et al.,
2011). Finally, DYRK1A is expressed and translocated from the
cytoplasm to the nucleus while the dendritic tree differentiated
independently in several neuronal populations (Hammerle et al.,
2003, 2008). In the adult mouse, the expression of Dyrk1a is
found in several brain regions both in the cytoplasm and the
nucleus (Marti et al., 2003).
The majority of the DYRK1A protein (almost 80%) is found
associated with the cytoskeletal fraction in human and mouse
brain, and the remaining protein is located in the cytosolic
and nuclear fractions (Marti et al., 2003; Kaczmarski et al.,
2014). The phosphorylated forms of DYRK1A are specific to
subcellular localization in human and mouse brain. With only
one residue phosphorylated (the conserved autophosphorylation
site Y321) in the cytosolic DYRK1A and multiple heterogeneous
phosphorylated sites found in the cytoskeletal and nuclear
DYRK1A (Kaczmarski et al., 2014). Thus the function of
DYRK1A could be regulated by the action of specific kinase(s)
that will influence its stability or its ability to localize to nuclear,
cytosolic or cytoskeletal compartments and thus to interact
with specific substrates. Indeed the nuclear accumulation of
DYRK2 is controlled by the “ataxia telangiectasia mutated”
(ATM) dependent phosphorylation. When phosphorylated by
ATM, DYRK2 dissociates from MDM2 (“transformed mouse
3T3 cell double minute 2”) and is no more degraded in the
nucleus through a MDM2-dependent ubiquitination and thus
could accumulate (Taira et al., 2010). This finding affecting DYRK
localisation raises several questions such as whether a similar
mechanism exists for DYRK1A and how it will be perturbed if
there is an overdosage of the protein.
DYRK1A phosphorylates different targets depending upon
its cellular localization (Marti et al., 2003; Park et al., 2009;
Kaczmarski et al., 2014). It acts on a multitude of exogenous
protein substrates, including transcription factors [CREB, NFAT
(nuclear factor of activated T-cells), STAT3, FKHR, GLI1,
RNApol2], splicing factors (cyclin L2, SF2, SF3), a translation
factor (eIF2Be), miscellaneous proteins (glycogen synthase,
caspase-9, Notch) or cytoskeletal target (TAU and MAP1B)
and synaptic proteins (dynamin I, amphiphysin I, synaptojanin
I; Table 1). Several targets listed here, might contribute to
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the role of DYRK1A in neuronal synaptic plasticity (Wegiel
et al., 2004; Aranda et al., 2008; Murakami et al., 2009, 2012).
Recent studies in Cos7 cells suggest that DYRK1A is involved
in the regulation of dendritic spine formation through Neural
Wiskott–Aldrich syndrome protein phosphorylation (Park et al.,
2012). At the synaptic level, DYRK1A could regulate synaptic
vesicle endocytosis via phosphorylation of AP180, dynamin I,
amphiphysin I, and synaptojanin I, as demonstrated in isolated
rat brain clathrin coated vesicle (Murakami et al., 2009, 2012).
Clathrin-mediated endocytosis is essential for the recycling of
membrane after neurotransmitter release (Saheki and De Camilli,
2012). DYRK1A is found in the pre-synaptic compartment of
the neuromuscular synapse (Arque et al., 2013). Conversely,
in the Drosophila neuromuscular junction, MNB acts as a
synaptic kinase that promotes efficient synaptic vesicle recycling
(Chen C.K. et al., 2014). Moreover, DYRK1A phosphorylation of
GRIN2A modifies the biophysical properties of GRIN1/GRIN2A,
two subunits of N-methyl-D-aspartate receptors (NMDAR) and
controls NMDAR activity in neurons, which are involved in
neural development, survival, synaptic plasticity and memory
processes (Grau et al., 2014).
DYRK1A Dosage and
Neurodevelopmental Diseases
DYRK1A is a paradigm of a dosage sensitive gene with its
underexpression, caused by heterozygous disruption or loss-of-
function mutations, leading to MRD7 and its overexpression
contributing to DS cognitive dysfunction. Such a variation
in gene dosage could have major impact on multiprotein
complex at the level of enzymatic activities or transcriptional
regulation (Figure 1) (Veitia et al., 2008). The first MRD7 cases
were translocation disrupting DYRK1A in two patients with
microcephaly, severe mental retardation without speech, anxious
autistic behavior, or dysmorphic features (Møller et al., 2008).
Then, a second study identified patients isolated from large
screen of 3,009 intellectually disabled individuals who presented a
de novo heterozygous deletion of the last three exons of DYRK1A
(van Bon et al., 2011). Several reports showed heterozygous
mutations in DYRK1A in patients with multiple phenotypes,
including developmental delays or intellectual disability with
autism spectrum disorder, microcephaly, epileptic seizures, facial
dysmorphisms and cardiac defects (Courcet et al., 2012; O’Roak
et al., 2012; Bronicki et al., 2015; Ruaud et al., 2015; Van Bon
et al., 2015) defining a new syndromic condition (Courcet et al.,
2012; Bronicki et al., 2015; Van Bon et al., 2015). Similar neuro-
developmental phenotypes (delay in eyelid and ear opening,
in the appearance of the righting reflex and of the Preyer’s
reflex), microcephaly, locomotor activity and coordination
(sensorimotor tets, balance, gait analysis, rotarod deficiency)
cognition defects (delay in the startle response, spatial memory
deficit in the Morris water maze and in the radial-arm water
maze, memory recognition in the object recognition paradigm)
and reduced dendritic tree of the layer III pyramidal cells were
observed in mouse heterozygous knockout models (Fotaki et al.,
2002; Benavides-Piccione et al., 2005; Dierssen and Martinez de
Lagran, 2006; Arqué et al., 2008, 2009). Homozygous Dyrk1a
knock-out (KO) mice die in utero with growth retardation,
reduced body size and morphological developmental delay
of the primitive organs. In an inbred genetic background,
newborn heterozygous KO mice have reduced neonatal viability
and decreased body size (Fotaki et al., 2002). Nevertheless,
approximately 30% of the heterozygous KO mutants can survive
in a mixed background. Their adult brains present increased
neuronal densities in some brain regions and a specific decrease
in the number of neurons in the superior colliculus, which
exhibits a significant size reduction (Fotaki et al., 2002).
The role of DYRK1A in DS is deduced from several studies
in mouse models. Mainly, mouse models overexpressing Dyrk1a
or trisomic for genomic segments, homologous to Hsa21 and
encompassing Dyrk1a, showed that Dyrk1a overdosage was
sufficient to impair cognition with defects similar to DS people
(For review see Ahn et al., 2006; Dierssen and Martinez de
Lagran, 2006; Dierssen et al., 2009; Guedj et al., 2012; Herault
et al., 2012). Several strategies to reduce the expression of Dyrk1a
in DS mouse models have shown that Dyrk1a overdosage was
necessary for DS related phenotypes. First, the normalization
of Dyrk1a expression was achieved via adeno-associated viral
delivery of a shRNA sequence specific for Dyrk1a. If injected in
the hippocampal region, hippocampal-dependent defects in long
term potentiation (LTP), a persistent increase in synaptic strength
following high-frequency stimulation of a chemical synapse,
and related memory performance (Morris water maze and fear
conditioning) were restored in Ts65Dn mice (Altafaj et al.,
2013). In addition, motor alterations were reduced after striatal
injection of AAV-shRNA in transgenic mice overexpressing
Dyrk1a (Ortiz-Abalia et al., 2008). These results demonstrated
that normalization of Dyrk1a expression in the adult brain
when neuro-developmental alterations have already occurred
is sufficient to ameliorate synaptic plasticity changes via its
effect on the Erk/CREB signaling pathway, that participates in
the LTP induction (Thomas and Huganir, 2004), considered
to be one of the major cellular mechanism sustaining learning
and memory (Bliss and Collingridge, 1993; Cooke and Bliss,
2006). Second, the normalization of Dyrk1a copy number in
trisomic mice was shown to improve hippocampal-dependent
learning, presumably due to the recovery of synaptic plasticity,
the enhancement of adult hippocampal cell proliferation and
differentiation and/or the improvement of the balance between
inhibitory and excitatory synaptic markers (Garcia-Cerro et al.,
2014; Jiang et al., 2015). In addition, three copies of Dyrk1a was
also shown to cause retinal structural and functional alterations
in trisomic mice, and normalization of Dyrk1a copy number
completely rescued both the morphological and functional visual
phenotypes (Laguna et al., 2013).
Overall the phenotypes observed in MRD7 and DS affect
similar areas and functions. Brain function is altered in both
conditions but with different impact on intellectual abilities. As
mentioned previously DS defects includes both short- and long-
term memory with delay in learning and in language acquisition
and comprehension (Chapman and Hesketh, 2000; Pennington
et al., 2003; Nelson et al., 2005; Abbeduto et al., 2007; Dierssen
et al., 2009; Contestabile et al., 2010; Lott and Dierssen, 2010)
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FIGURE 1 | Consequence of the dosage effect on the activity of a multiprotein complex. (A) Example of a dosage sensitive gene whose encoded protein (in
blue) is able to form a tripartite complex with two partners (in yellow or green), using different constant of association/dissociation. (B) The formation of the complex
will be altered by the level of expression of the blue protein compared to the yellow or green ones which are not dosage dependent here. With two copies of the
dosage sensitive genes, complexes will be formed with the expected 100% level of activity while in only one (or three copies) are expressed the corresponding
complexes will be disrupted delivering only partial activity that would lead when below (or above) a certain threshold to phenotypes. Adapted from (Veitia et al., 2008).
whereas in MRD7 autistic traits, repetitive behavior, feeding
difficulties are found associated with more severe intellectual
disabilities, speech delay or absence (Courcet et al., 2012; O’Roak
et al., 2012; Bronicki et al., 2015; Ruaud et al., 2015). The vision
is affected in both conditions but a more precise phenotypic
characterization is needed in MRD7. Microcephaly is observed
in MRD7 and in Dyrk1a heterozygous mice. Macrocephaly with
more precise regional morphological changes are detected in
transgenic mice overexpressing Dyrk1a alone (Guedj et al., 2012)
but the macrocephaly is not observed in DS mouse models such
as the Ts65Dn, suggesting that other genes are contributing to
the DS phenotypes (Jiang et al., 2015). Accordingly DS people
have a more reduced brain size, with a particular impact on
the cerebellum (Pinter et al., 2001; Guihard-Costa et al., 2006),
than the normal population. The microcephaly observed in
MRD7 should be a direct consequence of abnormal neuronal
progenitor proliferation and differentiation due to the loss-of-
function of DYRK1A, and induce delay in brain development.
On the opposite developmental changes do not seem to be
causing the defects rescued by normalizing DYRK1A in DS
models. Indeed treatment targeting DYRK1A in adult preclinical
model demonstrate that the increase in DYRK1A gene dosage
seems perturbed more the physiological function of DYRK1A
even though the situation should be more complex in both
diseases.
DYRK1A Dosage Variation and Impact on
Cellular and Molecular Mechanisms
Cognitive dysfunctions observed in MRD7 and in DS result from
DYRK1A misdosage during in utero development or in the adult
brain. As in MRD7, the DS brain volume is smaller (Guihard-
Costa et al., 2006), and this difference persists at post-natal
stages (Pinter et al., 2001). Development of the superior temporal
neocortex is abnormal with defect in axonal and dendritic
arborization (Becker et al., 1986; Golden and Hyman, 1994).
Several studies conducted in humans and DS mouse models have
suggested the presence of a defect in neurogenesis and increased
cell death in the hippocampus. This defect is probably due to
alterations of the cell cycle in neuronal progenitors (Contestabile
et al., 2007; Esposito et al., 2008; Guidi et al., 2008).
A number of studies have been conducted and demonstrate
that DYRK1A dosage is key role for neurogenesis and
neuronal maturation (for review see Park et al., 2009; Tejedor
and Haemmerle, 2011). DYRK1A regulates proliferation and
neuronal differentiation through the phosphorylation of p27Kip1
and Cyclin D1 (CCND1) (Hammerle et al., 2011; Soppa et al.,
2014). Dyrk1a gain of function experiments were shown to stop
cell proliferation with an increased number of cells expressing
p27Kip1, a cyclin dependent kinase inhibitor acting as a main
negative regulator of the cell cycle of neurons. Conversely its
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loss-of-function triggered proliferation and cell death through
a p27Kip1 downregulation (Hammerle et al., 2011). Dyrk1a
transient expression control the neuronal precursor exit from
differentiation through CCND1 and P27Kip1, leaving the cells
in a quiescent state ready to differentiate while its expression
reduced (Hammerle et al., 2011). DYRK1A can also regulate
the G1-phase of the cell cycle of fibroblast cells through the
direct phosphorylation of CCND1 (at T286), its nuclear export,
degradation, and relative level with p21, all together determining
the cycle entry versus exit decision. As such the G1 phase is
extended in trisomic fibroblasts due to a lower CCND1 level
that could be counteracted by inhibiting DYRK1A (Chen et al.,
2013). The same mechanism has been found while DYRK1A
controls the cell exit of ventricular neuronal progenitor cells in
mouse embryos. In this compartment, Dyrk1a overexpression,
through in utero electroporation of mouse embryos, inhibits cell
cycle progression and induces premature neuronal differentiation
without affecting the capacity to migrate or to differentiate
in the post-natal cortex (Yabut et al., 2010). Accordingly in
transgenic Dyrk1a mouse embryos, the G1 phase is increased in
progenitor cortical stem cells due to CCND1 phosphorylation
by DYRK1A, producing a deficit in cortical projection neurons
that persists in postnatal stages (Najas et al., 2015). This
phenotype is also present in the Ts65Dn DS mouse model which
are trisomic for a large region homologous to the human
chromosome 21.
Nevertheless additional mechanisms are also perturbed by
change in DYRK1A dosage. DYRK1A interferes with the
NFATc pathway that is critical for the regulation of vertebrate
development, organogenesis and neuronal development (Graef
et al., 2001; Nguyen and Di Giovanni, 2008). Overexpression
of Dyrk1a acts synergistically with GSK3, as a priming
kinase, to inhibit NFAT-dependent transcription in cortical
neurons stimulated by FGF8 and heart valve elongation during
development of the Ts1Cje DS models, through increase in
NFAT nuclear export (Arron et al., 2006). Conversely DYRK1A
and DYRK2 were found to phosphorylate NFAT regulatory
domain in Drosophila (Gwack et al., 2006). As expected
overexpression of both Dyrk1a and Rcan1 results in delayed
differentiation of neuronal progenitor cells, with a marked
cell-cycle re-entry and alteration of laminar positioning. This
phenomenon leads to a reduction of nuclear NFAT localization
and can be rescued by expressing a constitutively active form of
NFAT (Kurabayashi and Sanada, 2013). As expected interfering
with Rcan1 or Dyrk1a overdosage in the Ts1Cje models, or
expressing the same constitutive active form of NFAT, rescue
the differentiation process, found affected in the trisomic
mice. As such the deregulation of the DYRK1A/RCAN1/NFAT
pathway leads to developmental alterations which should
impact brain size and neuronal density, two traits altered
in DS.
In addition, the aberrant enhancement of astrocytic
differentiation of cortical progenitor cells has been described
in the Ts1Cje mouse model. It is promoted by DYRK1A acting
on STAT3, a transcription factor critical for astrogliogenesis
(Kurabayashi et al., 2015). This defect could be related to
phenotypes observed in DS astroglia. Indeed, differentiation
of human induced Pluripotent Stem cells (hiPSc)-from DS
patients revealed defect in the neuronal maturation, synapse
formation and neurogenesis due to specific overexpression
of S100B in medium derived from hIPSc-derived astrocytes
(Chen C. et al., 2014). Unfortunately, no S100b-dependent
and specific phenotypes have been found so far in DS
trisomic models (Yu et al., 2010a,b; Duchon et al., 2011;
Belichenko et al., 2015; Jiang et al., 2015) (Duchon and
Herault, personal communication) but further analysis in
older individuals or to address the function of the tripartite
synapse (Pereira and Furlan, 2010) might unravel additional
changes.
Overall the variation in DYRK1A activity may impact the
proliferation of progenitors cells, the function of the REST
complex, leading to the microcephaly observed in MRD7 while
in DS premature differentiation will lead to a reduced pool of
mature neurons. Presumably both mechanism will contribute
to the decreased brain size observed in DS, and cell density
alterations found in animal models.
DYRK1A controls neuronal morphogenesis by regulating
cytoskeletal dynamics, and overexpression of Dyrk1a in mice
is sufficient to recapitulate the dendritic alterations observed
in DS patients (Martinez de Lagran et al., 2012). In the
adult, connectivity and plasticity are also impacted at different
levels. In trisomic mice, dendritic arbor size of neocortical
pyramidal cells is smaller, and the peak branching in the
arbor was less complex (Dierssen et al., 2003). Total synapse
density and synapse-to-neuron ratios are significantly lower in
trisomic context (Kurt et al., 2004). Pre-synaptic and post-
synaptic elements are significantly enlarged in the hippocampus,
the motor and somatosensory cortex, the entorhinal cortex,
and the medial septum (Belichenko et al., 2004). Moreover,
there is a significant alteration of inhibitory synapses in
the fascia dentata (Belichenko et al., 2009). These defects
are probably responsible of changes in LTP and long-term
depression (LTD), which have been observed in DS mouse
models (Siarey et al., 1997, 1999, 2005; Kleschevnikov et al.,
2004; Belichenko et al., 2007; Fernandez et al., 2007). Among
other possible mechanisms, reduced N-methyl-D-aspartate
(NMDA) receptor activation may contribute with an excessive
GABAergic inhibition (Kleschevnikov et al., 2004; Costa and
Grybko, 2005; Belichenko et al., 2007). In addition increase in
GABAergic neurons and changes in the excitatory/inhibitory
balance are observed in DS models (Altafaj et al., 2008;
Grau et al., 2014; Souchet et al., 2014). Both observations
are important but nothing is known at present linking
DYRK1A to the glutamatergic synapse or to the GABAergic
neurons.
Finally, in the later stages of life, DS patients present a
neuropathology similar to AD that will evolve in dementia
for 80% of patients after the age of 65 (Strydom et al.,
2010; McCarron et al., 2014). This degenerative modification
appears in conjunction with the presence of Aβ and tau
lesions in several brain regions (Wisniewski et al., 1985).
Additionally, a deficit in cholinergic neurons similar to
the deficit that occurs in AD has been observed in DS
during aging (Contestabile and Ciani, 2008). Even if there
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is a high prevalence of dementia, not every DS patient
develops the accompanying clinical symptoms (Nieuwenhuis-
Mark, 2009). Interestingly, overexpression of DYRK1A and
some direct targets, such as APP and MAPT, contributes to
the early onset of neurofibrillary degeneration, β-amyloidosis,
neuronal loss and dementia in DS (Rovelet-Lecrux et al.,
2006, 2010; Salehi et al., 2006; Liu et al., 2008; Wegiel et al.,
2011; Rovelet-Lecrux and Campion, 2012; Park and Chung,
2013).
DYRK1A is expressed in the nucleus and can also control
the expression and interact transcription factor such as the
RE1-silencing transcription factor/neuron-restrictive silencer
factor REST/NRSF–SWI/SNF chromatin remodeling complex
(Canzonetta et al., 2008). Through these mechanisms, increase
of Dyrk1a gene dosage induces a SWI/SNF-linked deregulation
of gene clusters involved in the neuronal phenotypic traits of
DS (Lepagnol-Bestel et al., 2009). Dyrk1a overexpression also
leads to alteration in the transcriptome, and these changes
affect the NMDA type glutamate receptor with an alteration
of NMDA-induced calcium dynamics (Grau et al., 2014). More
recently DYRK1A has been showed to act as a transcription
factor, phosphorylating the carboxy terminal domain of the RNA
polymerase 2 in HeLa cells (Di Vona et al., 2015). Nevertheless
no evidence have been found yet for an impact of DYRK1A
dosage on the direct interaction of DYRK1A with the RNApol
2 in MRD7 or DS models.
AN ERUPTION OF DYRK1A KINASE
INHIBITORS
Inhibition of DYRK1A activity represents a new field of study,
and a growing number of active molecules to target this protein
have been isolated over the last 5–10 years (for review see Becker
and Sippl, 2011; Ionescu et al., 2012; Smith et al., 2012; Tell and
Hilgeroth, 2013; Becker et al., 2014; Abbassi et al., 2015).
Historically, several compounds were isolated that exhibit
dual inhibition of both DYRK family members and cell division
cycle-like kinase (CLK family kinases). Effectively, the CLK
and DYRK kinase families are part of the CMGC group of
the eukaryotic kinome; this group, named after the initials
of some members, exhibits auto-phosphorylation activity in
addition to phosphorylating serine and tyrosine residues of
specific substrates (Aranda et al., 2011). The CLK family has been
targeted for the regulation of alternative splicing. CLK family
kinases are involved in controlling HIV-1 gene expression (Wong
et al., 2011), hepatic gluconeogenesis (Rodgers et al., 2010),
cancer (Liu et al., 2013) and neurodegenerative disease such as
AD, and their inhibition can be used as a therapeutic strategy
(Jain et al., 2014). Thus, many inhibitors have been developed in
recent years and are still under investigation for the treatment of
DS.
Several compounds with inhibitory activity were originally
isolated from natural sources. For example, harmine, a
β-carboline alkaloid with a pyrido[3,4-b]indole ring structure
was first isolated from the South American vine Banisteriopsis
caapi. This molecule has been shown to be an ATP-competitive
inhibitor of DYRK1A in vitro, with less potency against other
DYRK family members (Laguna et al., 2008; Gockler et al., 2009;
Adayev et al., 2011). Tg(Dyrk1a) mice, which overexpress Dyrk1a
like people with DS, treated with harmine showed a significant
decrease of homocysteine and liver ERK1/2 phosphorylation
(Noll et al., 2012). Additionally, harmine prevents premature
maturation of neuronal progenitors isolated from Ts65Dn
(Mazur-Kolecka et al., 2012). Finally, harmine or its derivatives
have been shown to reduce the levels of multiple phosphorylated
forms of tau protein in tau overexpressing H4 neuroglioma cells,
which are important in the pathological progression of AD (Frost
et al., 2011). However, β-carboline analogs possess additional
properties such as the inhibition of monoamine oxidase A, a
target for depression (Kim et al., 1997), but with significant
drawbacks, such as their hallucinogenic properties and a plethora
of psychoactive effects, which limit their use in vivo (Fuentes
and Longo, 1971). The flavonoid epigallocatechin-3-gallate
(EGCG) was the second compound used but the first to be
shown to improve cognition in DS models and in humans.
Flavanoids, are characterized by having a benzopyrane skeleton,
with a pyrane ring bearing at least one aromatic ring. EGCG is
also a natural polyphenol and is a major catechin component
of green tea leaves (Camellia sinensis) and was identified as
a non-competitive ATP inhibitor of DYRK1A (Bain et al.,
2003; Adayev et al., 2006). Both EGCG and harmine can
fully restore the endocytic defects of hippocampal neurons in
mouse models that overexpress Dyrk1a (Kim et al., 2010). In
human DS- iPSCs, DYRK1A inhibition by EGCG treatment
during neural induction and neuronal differentiation induces
an improvement in the number of neurons and promotes
dendritic development (Hibaoui et al., 2014). In vivo and
in vitro studies of DS mouse models treated with a green tea
extract or EGCG extract demonstrated an improvement in brain
structure, adult neurogenesis, synaptic plasticity and learning
and memory (Xie et al., 2008; Guedj et al., 2009; Pons-Espinal
et al., 2013; De la Torre et al., 2014). EGCG also regulates the
expression of REST, which is a modulator of genes that encode
fundamental neuronal functions, via inhibition of DYRK1A
in embryonic stem cells and in the mouse cortex (Canzonetta
et al., 2008). Moreover, a pilot study of EGCG in young adults
with DS demonstrated effects on memory recognition, working
memory and quality of life (De la Torre et al., 2014). EGCG
has been demonstrated to be a safe substance after repeated
administration in humans and can be easily found as a dietary
supplement because of its anti-oxidant properties (Kanwar et al.,
2012). A second trial (phase II) has already been conducted by
Dierssen and coworkers, and the results are highly anticipated.
However, some problems with this compound remain, such as
its complex pharmacokinetic properties, poor bioavailability,
multiple and heterogeneous effects on signaling pathways and
the degree of purity of the commercially available compound
(Lambert et al., 2007; Kanwar et al., 2012; Lorenz, 2013). In
addition, EGCG was found to have a low inhibitory effect on
cannabinoid receptor 1 (CNR1) activity (Korte et al., 2010),
which could have negative consequences for long-term treatment
as the well-known rimonabant, an inverse agonist directing
CNR1. Rimonabant was used as an anorectic and antiobesity
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drug and was removed from the market after reports of severe
depression and suicide in treated people (Thomas et al., 2014).
Thus, it is essential to concentrate future efforts on finding a
more specific DYRK1A inhibitor, with no interference with
CNR1.
Other inhibitors were isolated from natural sources. This
is the case for several marine alkaloids, such as variolins,
a family containing a central pyrido[3′,2′:4,5]pyrrolo[1,2-c]
pyrimidine core substituted with a 2-aminopyrimidine ring and
meridianins, and a family of 3-(2-amino-pyrimidine)indoles
(Gompel et al., 2004; Giraud et al., 2011; Tahtouh et al., 2012)
as well as meriolins, which are a chemical hybrid between
the natural products meridianins and variolins (Echalier et al.,
2008). Olomoucine is one of the first CDK inhibitors to be
developed, and two of its derivatives, family members of 2,6,9-
trisubstituted purines roscovitine and purvalanol, also act on
DYRK1A (Vesely et al., 1994; Gray et al., 1999; Bain et al.,
2003). Staurosporine belongs to the class of indolocarbazoles,
which bear a single sugar residue bound to both indole nitrogens,
and was originally isolated from the bacterium Streptomyces
stauroporus. This compound has exhibited potential as an
inhibitor of DYRK1A, but its inhibitory activity was not
selective enough among a large array of kinases (Sanchez et al.,
2009).
Many inhibitors of DYRK1A kinase activity that have been
developed so far are type I inhibitors; i.e., they target the ATP
binding site of the kinase in its active conformation when
the activation loop is phosphorylated. They have a chemical
structure close to the adenine nucleus like many nitrogen
heterocyclic compounds such as quinoline, quinazolines,
pyrimidines, pyrrolopyrimidines, pyrrolopyridines, and
pyrazolopyrimidines. These heteroaromatic cores are often
capable of highly efficient binding to proteins because of
their shape and hydrophobic nature. Their advantages are
their lack of flexibility combined with hydrogen bonding
potential from their heteroatoms that can provide a level
of target selectivity. Additionally, a rapid exploration of the
effect of adding different substituents is facilitated by the
applicability of parallelizable reactions, and finally, two or more
substitution positions can be explored without the complication
of introducing a stereocenter. Their major disadvantages
are their hydrophobic nature and flat shape, resulting in
low aqueous solubility (Pitt et al., 2009). These inhibitors
have higher potency on substrate phosphorylation than on
autophosphorylation. Serine and threonine phosphorylation of
substrates is inhibited with lower impact on autophosphorylation
and the remaining tyrosine kinase activity. Such a difference may
reflect the accessibility of the inhibitor target site. DYRK1A
kinase activity is closely regulated, with two successive
conformational states proposed: the first immature state
allows the enzyme to act on the tyrosine residue, while the
second more mature state, being irreversible, reacts with the
serine/threonine residue (R(X1−2)S/TP) (Lochhead et al.,
2005). The two-states model was enriched with the two
conformations having slight differences in reacting with tyrosine
or serine/threonine, with the immature state having lower
catalytic activity and different equilibrium for the amino
acid than the mature state (Walte et al., 2013). Additionally,
several inhibitors have been synthesized, such as Tg003
(Muraki et al., 2004) and INDY (Ogawa et al., 2010) two
benzothiazole derivatives. For example, DANDY, a new 3,5-
diaryl-7-azaindole that demonstrates potent inhibition against
DYRK1A kinase activity (Gourdain et al., 2013). HCD160
and its derivatives (Kim N.D. et al., 2006; Koo et al., 2009),
a series of substituted 6-arylquinazolin-4-amines (Mott et al.,
2009; Rosenthal et al., 2011), a new 3-(6-hydroxyindol-
2-yl)-5-(phenyl)pyridine (Kassis et al., 2011), a series of
aryl-substituted aminopyrimidines (Coombs et al., 2013), a new
7-substituted pyrido[2′,3′:4,5]furo[3,2-d]pyrimidin-4-amines
(Deau et al., 2013), an 8-arylpyrido[30′20′:4,5]thieno[3,2-
d]pyrimidin-4-amines (Loidreau et al., 2015), and a series
of hydroxybenzothiophene ketones (Smith et al., 2012;
Schmitt et al., 2014). To date, no DYRK-specific or CLK-
specific inhibitors have been reported, certainly because
there is a high degree of conservation of the ATP binding
site inside the CLK and DYRK kinase families. Nevertheless
novel interesting compounds are in development (Rüben
et al., 2015). Even if some cellular side effects have been
reported for several of the listed compounds, none of them
have yet been tested in DS models. Moreover, the activity
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of these compounds is usually stronger on CLK kinases,
excluding varioline B, leucettine 41 and harmine (Tahtouh et al.,
2012).
Recent progress on more specific and selective inhibitor has
already been made. For example, we note the development of a
new bioluminescent reporter assay for evaluation of DYRK1A
inhibitors. This system led to the identification of (Z)-5-[(2,3-
dihydrobenzofuran-5-yl)methylene]-2-iminothiazolidin-4-one
(referred to as CaNDY: CDC37 association inhibitor for
DYRK1A) as a strong inhibitor of DYRK family kinases. In
addition to inhibition potential, CaNDY decreases DYRK1A
molecules in cells, thus efficiently suppressing DYRK1A
activity compared to simple inhibition of kinase activity
(Sonamoto et al., 2015). Substituted quinazolines are a common
pharmacophore for ATP-competitive kinase inhibitors, and
the 5 novel thiazolo[5,4-f]quinazoline derivatives that have
been synthesized (EHT 5372, 6840, 1610, 9851 and 3356) are
among the most potent DYRK1A/1B inhibitors disclosed to
date. In particular, they are more potent than NCGC-00189310
(Rosenthal et al., 2011) and leucettine L41 (Tahtouh et al.,
2012), the two most active reference inhibitors tested during
the screening campaign (Foucourt et al., 2014; Coutadeur
et al., 2015). In addition, an indirubin derivative was inactive
toward cyclin-dependent kinase 5 (CDK5), GSK3β, and casein
kinase 1 (CK1) while exhibiting good selectivity and affinity for
DYRK kinases (Myrianthopoulos et al., 2013). Consequently,
the development of type II or III inhibitors, non-ATP-mimetics
that are anchored to more diverse regions of the ATP binding
site, may result in more selective inhibitors while also targeting
the premature DYRK1A kinase. For example KHCB19 is a
dichloroindolyl enaminonitrile derived from bauerine C, a
β-carboline alkaloid originally isolated from the blue-green
alga Dichothrix baueriana. This compound exhibits a unique
‘non-ATP mimetic like’ binding mode to CLK1 and also acts
on DYRK1A (Fedorov et al., 2011). The non-ATP competitive
inhibitors, called type II and type III inhibitors act by inducing a
conformational shift in the target enzyme such that the kinase
is no longer able to function. This unusual binding mode
highlights the opportunity to develop very potent and specific
inhibitors with new chemical profiles because they offer the
possibility to overcome the major problem of the type I inhibitor
(Garuti et al., 2010). Nevertheless even if a more potent and
specific inhibitor would be better, too much inhibition may
be deleterious as in the case of loss-of-function mutation of
DYRK1A in MRD7. In addition DYRK1A specific inhibition on
substrates phosphorylation versus autophosphorylation would
be interesting to determine. A specific substrate kinase inhibition
may have a more beneficial effect rather than targeting the
autophosphorylation. The situation is even more complex
considering that the target site of the inhibitor might have
different accessibility depending on the two conformations of
DYRK1A.
Modulation of DYRK1A in MRD7 by increasing its activity
would be a good strategy to alleviate the severe cognitive
deficits present in the disease, in particular for loss-of-function
mutations. Nevertheless only a few proteins are known to
increase DYRK1A activity (see Table 2) and no DYRK1A
compound activator has been described to date. Thus further
work is needed to investigate such a strategy for MRD7.
CONCLUSION
Major steps have been achieved to establish the role of
DYRK1A in intellectual disabilities such as DS and MRD7
syndromic condition involving heterozygous loss-of-function
mutations affecting DYRK1A. These two neurodevelopmental
disorders share common features resulting from the alteration of
DYRK1A-controlled mechanisms such as neuronal proliferation
and differentiation. However, many questions on DYRK1A
inhibitors remain unanswered. Are type 1 DYRK1A inhibitors
blocking the ATP binding site better suited than type 2 or 3
inhibitors selective for a particular conformation of DYRK1A?
What are the cellular targets of DYRK1A: GABAergic or
glutamatergic neurons, glial cells?
Undeniably DYRK1A inhibitors represent a promising class of
molecules to improve cognitive deficits in people with DS. The
pilot clinical trials in adults treated with EGCG is promising,
showing a modest gain of cognition (De la Torre et al., 2014).
Perinatal treatment during earlier phases of brain development is
attractive for improving synaptic plasticity, keeping in mind that
DYK1A plays an important role in brain growth by controlling
neuronal proliferation and differentiation. Additional studies will
be needed to evaluate the use of DYRK1A inhibitors during
perinatal periods.
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